RIPK3
MOLECULAR TARGETreceptor interacting serine/threonine kinase 3
RIPK3 (receptor interacting serine/threonine kinase 3) is targeted by 36 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting RIPK3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gefitinib | 5.67 | 290 |
| 2 | ibrutinib | 4.86 | 128 |
| 3 | cabozantinib | 4.39 | 80 |
| 4 | foretinib | 4.34 | 76 |
| 5 | ponatinib | 4.26 | 70 |
| 6 | nilotinib | 4.17 | 64 |
| 7 | quizartinib | 3.99 | 53 |
| 8 | silmitasertib | 3.78 | 43 |
| 9 | pazopanib | 3.69 | 39 |
| 10 | regorafenib | 3.56 | 34 |
| 11 | canertinib | 3.53 | 33 |
| 12 | gilteritinib | 3.40 | 29 |
| 13 | saracatinib | 3.33 | 27 |
| 14 | fexagratinib | 3.33 | 27 |
| 15 | dabrafenib | 3.30 | 26 |
| 16 | gw305074x | 3.14 | 22 |
| 17 | dacomitinib anhydrous | 3.14 | 22 |
| 18 | lenvatinib | 3.04 | 20 |
| 19 | galunisertib | 2.94 | 18 |
| 20 | tivozanib | 2.64 | 13 |
| 21 | linsitinib | 2.64 | 13 |
| 22 | motesanib | 2.48 | 11 |
| 23 | poziotinib | 2.48 | 11 |
| 24 | rebastinib | 2.20 | 8 |
| 25 | golvatinib | 2.20 | 8 |
| 26 | encorafenib | 2.20 | 8 |
| 27 | cyc 116 | 2.08 | 7 |
| 28 | tg100 115 | 2.08 | 7 |
| 29 | osi 930 | 2.08 | 7 |
| 30 | cep 32496 | 1.95 | 6 |
| 31 | bafetinib | 1.95 | 6 |
| 32 | sapitinib | 1.95 | 6 |
| 33 | tucatinib | 1.95 | 6 |
| 34 | rivoceranib | 1.95 | 6 |
| 35 | varlitinib | 1.79 | 5 |
| 36 | Vemurafenib | 0.69 | 1 |
About RIPK3 as a Drug Target
RIPK3 (receptor interacting serine/threonine kinase 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 36 compounds with documented RIPK3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
RIPK3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.